Statin and Ezetimibe for Heart Disease and Kidney Disease
Treatments studied
Part of Heart & circulation, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether taking a moderate-strength statin (cholesterol-lowering drug) plus ezetimibe (another cholesterol medicine) together helps protect the heart and kidneys in people who have both chronic kidney disease and established heart disease or stroke history.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Between 19 and 85 years old
- Chronic kidney disease stage III, IV, or V (reduced kidney function measured by blood test or on dialysis)
- History of heart attack, unstable angina, coronary stent/bypass, leg artery disease, or stroke/mini-stroke
- Not currently on statin therapy with LDL cholesterol ≥55 mg/dL (or already on a statin)
- No severe liver disease or unexplained liver enzyme elevation
- No statin allergy and able to commit to at least 1 year of follow-up visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination pill of two cholesterol-lowering medicines (pitavastatin and ezetimibe) in adults who have been taking either atorvastatin or rosuvastatin for at least 3 months. It aims to see if switching to this new combination is safe and effective.
This trial studies whether high-intensity statin plus ezetimibe can improve heart health in people who do not have symptoms but have calcium buildup in their heart arteries. It may help lower cholesterol and reduce future heart risks for the right participants.
This study compares two different ways of lowering cholesterol: a moderate statin (pitavastatin) plus another drug (ezetimibe) versus a stronger statin alone. The goal is to see which approach is safer regarding the risk of developing new diabetes.
This trial compares a high-dose combination of rosuvastatin (a statin) and ezetimibe (another cholesterol-lowering drug) versus a standard rosuvastatin-only approach for people with peripheral artery disease (narrowed leg arteries) or widespread artery disease. The goal is to see which strategy better lowers LDL cholesterol and reduces heart and limb risks.
This trial tests if pitavastatin alone or with ezetimibe affects blood sugar differently than atorvastatin in people who have heart or blood vessel disease and metabolic syndrome but do not have diabetes.
This trial compares two cholesterol-lowering approaches in people with prediabetes to see which one is less likely to lead to new-onset diabetes. It may help you choose a safer medication plan if you need strong cholesterol treatment to prevent future heart problems.
Hear when a new Renal Insufficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.